Acknowledgements
This study was funded by Biogen. Biogen acquired Nightstar Therapeutics in 2019. Nightstar Therapeutics designed the trial with the academic authors before the acquisition. Biogen provided timrepigene emparvovec to trial sites, analyzed the data and funded medical writing support for manuscript development. The authors thank the STAR study investigators who participated in the conduct of the study. The full list of STAR study investigators and their affiliations is included in Supplementary Table 